Enzyme News and Research

RSS

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

SARS-CoV-2 spike mutations during transmission among humans and to animals

A fascinating new study discusses the 40 mutations that are seen on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and their potential effects on viral biology.

3 May 2021

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

A new study, released as a preprint on the bioRxiv* server, reports promising results with the natural product hopeaphenol, which successfully prevented the entry of the virus into host cells.

3 May 2021

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Researchers at the Eberhard Karls University and the University of Tübingen in Germany described 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potentially inhibit the connection of RBD with the angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States have conducted a study demonstrating the effectiveness of first-generation vaccines at protecting against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals who have previously been infected with the virus.

2 May 2021

Too much salt affects the functioning of phagocytes

For many of us, adding salt to a meal is a perfectly normal thing to do. We don't really think about it. But actually, we should. As well as raising our blood pressure, too much salt can severely disrupt the energy balance in immune cells and stop them from working properly.

30 Apr 2021

Applications of nanoparticles in combating COVID-19

Researchers review the various properties and use of nanoparticles in targeting SARS-CoV-2 and how they could be used to develop new therapeutics and diagnostics for SARS-CoV-2.

30 Apr 2021

Novel integrative genetic screening platform offers insights into role of DNA accessibility in cancer

In a new resource for the scientific community, published today in Nature Biotechnology, researchers in the lab of Neville Sanjana, PhD, at the New York Genome Center (NYGC) and New York University (NYU) developed CRISPR-sciATAC, a novel integrative genetic screening platform that jointly captures CRISPR gene perturbations and single-cell chromatin accessibility genome-wide.

30 Apr 2021

New medical publication offers guidelines on how to manage patients with unexplained low blood sugar

A collaboration between experts and a Danish-based, global reaching patient organization has resulted in a groundbreaking medical publication, where guidelines are being presented on how to manage patients with unexplained low blood sugar.

30 Apr 2021

Human to animal transmission of SARS-CoV-2 in households is common

Coronaviruses are seen in multiple mammalian species. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the COVID-19 pandemic, is said to have passed to humans from a mammalian source and to have originated from an animal reservoir as a zoonotic pathogen.

29 Apr 2021

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

Researchers in the Republic of Korea (South Korea), The Netherlands, and South Africa have demonstrated the potential of the monoclonal antibody CT-P59 as an effective therapeutic for coronavirus disease 2019 (COVID-19) caused by the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Apr 2021

"COVID-19 diarrhea" depends on inflammatory response that is part of the disease

Researchers in the United States have provided important insights into the pathophysiology of diarrhea that occurs in some cases of coronavirus disease 2019 (COVID-19).

29 Apr 2021

Novel compound in avocados may offer a route to better leukemia treatment

A compound in avocados may ultimately offer a route to better leukemia treatment, says a new University of Guelph study.

29 Apr 2021

Obesity and high-salt diet pose bigger, seemingly synergistic cardiovascular risks for females

Obesity and a high-salt diet are both bad for our hearts but they are bigger, seemingly synergistic risks for females, scientists report.

29 Apr 2021

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of SARS-CoV-2 variants. The team analyzed the impact of potential mutations in the spike RBD on antibody efficacy.

29 Apr 2021

Researchers discover how SARS-CoV-2 hijacks human cell machinery to blunt immune response

Researchers at University of California San Diego School of Medicine have discovered one way in which SARS-CoV-2, the coronavirus that causes COVID-19, hijacks human cell machinery to blunt the immune response, allowing it to establish infection, replicate and cause disease.

29 Apr 2021

COVID-19 donor antibodies show broad cross-reactivity against SARS-CoV-2 variants and related viruses

A new study reports on a set of antibodies from COVID-19 donor serum, which seems to be cross-reactive across multiple Sarbecoviruses, including the very similar SARS-CoV-2, SARS-CoV and Middle East Respiratory Syndrome (MERS)-CoV.

28 Apr 2021

SARS-CoV-2 recruits heme metabolites in antibody evasion

A research paper recently published in the journal Science Advances by Cherepanov et al. (April 22nd, 2021) demonstrated that the NTD binds to biliverdin, a product of heme catabolism, leading to enhanced antibody escape at physiologically relevant concentrations.

28 Apr 2021

Why do we lose our sense smell/taste with COVID?

The angiotensin-converting enzyme 2 (ACE2) enzyme attached to the membranes of cells is the entry point for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They are abundantly found all over the body and most prominently in the lungs and nose.

28 Apr 2021

Enzyme News and Research

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

SARS-CoV-2 spike mutations during transmission among humans and to animals

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Too much salt affects the functioning of phagocytes

Applications of nanoparticles in combating COVID-19

Novel integrative genetic screening platform offers insights into role of DNA accessibility in cancer

New medical publication offers guidelines on how to manage patients with unexplained low blood sugar

Human to animal transmission of SARS-CoV-2 in households is common

Monoclonal antibody CT-P59 shows preclinical efficacy against South African SARS-CoV-2 variant

"COVID-19 diarrhea" depends on inflammatory response that is part of the disease

Novel compound in avocados may offer a route to better leukemia treatment

Obesity and high-salt diet pose bigger, seemingly synergistic cardiovascular risks for females

Researchers characterize a large set of therapeutic antibodies against SARS-CoV-2 variants

Researchers discover how SARS-CoV-2 hijacks human cell machinery to blunt immune response

COVID-19 donor antibodies show broad cross-reactivity against SARS-CoV-2 variants and related viruses

SARS-CoV-2 recruits heme metabolites in antibody evasion

Why do we lose our sense smell/taste with COVID?

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo